[Federal Register: November 13, 1998 (Volume 63, Number 219)]
[Notices]               
[Page 63496]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr13no98-113]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division

 
Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Axys Pharmaceuticals, Inc./Luminex Corporation

    Notice is hereby given that, on September 15, 1998, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Axys Pharmaceuticals, Inc./
Luminex Corporation has filed written notifications simultaneously with 
the Attorney General and the Federal Trade Commission disclosing (1) 
the identities of the parties and (2) the nature and objectives of the 
venture. The notifications were filed for the purpose of invoking the 
Act's provisions limiting the recovery of antitrust plaintiffs to 
actual damages under specified circumstances. Pursuant to Section 6(b) 
of the Act, the identities of the parties are Axys Pharmaceuticals, 
Inc., La Jolla, CA; and Luminex Corporation, Austin, TX. The nature and 
objectives of the venture are to develop and demonstrate technology 
that will be applied to the fields of gene discovery and DNA 
diagnostics. The technology is based on the manipulation of thousands 
of elements in arrays in miniature (microarray technology) and will 
utilize methods that are innovative and proprietary.
Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 98-30421 Filed 11-12-98; 8:45 am]
BILLING CODE 4410-11-M